GastroenteroloGy
Comprehensive disease testing
A collaboration with BioPharma Diagnostics includes access to the gastroenterology disease testing capabilities of Mayo Clinic Laboratories, including:
- Inflammatory bowel disease
- Therapeutic drug monitoring
- Intestinal infections
- Chronic liver disease
- Celiac disease
- Pancreatic disease
- Autoimmune testing
- Metabolite monitoring
- Noninvasive mucosal healing tests
- Antibody testing
BioPharma Diagnostics partners can access gastroenterology testing for clinical trials and be among the first to use up-and-coming tests currently in development.
News and updates
The latest
Register now – Nov. 12, 2025 - PACE/State of FL - Review known genetic predisposing factors to acute or chronic pancreatitis, as well as define who may benefit from genetic testing.
In this month’s Hot Topic, Robin Patel, M.D., discusses Mayo Clinic Laboratories’ new PCR assay for detection of Helicobacter pylori detection and determination of clarithromycin resistance directly from stool.
Thank you to our staff at Mayo Clinic who step up daily during this time of need to provide access to testing during the global pandemic. We appreciate each one of you and all the sacrifices you personally have made throughout this past year.
Puanani Hopson, D.O., a Mayo Clinic pediatric gastroenterologist, explains the pancreatic elastase test — a screening test that can be useful when symptoms point to the possibility of exocrine pancreatic insufficiency. Dr. Hopson reviews when this test should be ordered, how it compares to other test options, and how its results can guide further evaluation.
A small but in-depth study conducted a postmortem evaluation of the heart tissue of 15 patients with COVID-19, including the first postmortem cardiac findings of three patients who had cleared the virus.
Joshua Bornhorst, Ph.D., associate director of Mayo Clinic's Clinical Immunoassay Lab, explains how humans can develop an allergy to the alpha-gal molecule, and he describes a new allergen antibody test that can be used to detect it. Dr. Bornhorst also reviews other tests that should be used in conjunction with alpha-gal testing to accurately identify the scope and underlying cause of the allergy.
Divyanshu (Div), Dubey, M.B.B.S, gives an overview of the new Autoimmune Gastrointestinal Dysmotility Evaluation available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing compares to previous testing approaches, and what clinical action can be taken due to the results of this testing.
Joseph Yao, M.D., gives an overview of this new test available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing improves upon other testing approaches, and what clinical action can be taken due to the results of this testing.
Nikola Baumann, Ph.D., gives an overview of the new NASH-FibroTest available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing improves upon previous testing approaches, and what clinical action can be taken due to the results of this testing.
Many patients may have flare-ups of their disease, or they may stop responding to treatment. In these situations, the clinician may choose to increase the dose administered or recommend more frequent injections. One cause of decreased response to treatment is the appearance of anti-drug antibodies or “immunogenicity.”
Ann Moyer, M.D., Ph.D., discusses an additional gene, NUDT15, which is important in the prediction of thiopurine-related toxicity This gene has been added to our TPMT genotyping assay available through Mayo Medical Laboratories.
Detection of individuals with low thiopurine methyltransferase (TPMT) activity who are at risk for excessive myelosuppression or severe hematopoietic toxicity when taking thiopurine drugs.